Document is current
Any future updates will be listed below
-
Authors
Rodère, Malory https://orcid.org/0000-0002-3669-7132
Pereira, Bruno https://orcid.org/0000-0003-3778-7161
Soubrier, Martin https://orcid.org/0000-0001-9349-0720
Fayet, Françoise https://orcid.org/0000-0002-5491-2262
Piperno, Muriel https://orcid.org/0000-0002-0786-3752
Pallot-Prades, Béatrice
Pouplin, Sophie https://orcid.org/0000-0002-5797-4813
Baudens, Guy
Cohen, Jean-David https://orcid.org/0000-0003-0636-9653
Coquerelle, Pascal https://orcid.org/0000-0002-8475-8518
Grange, Laurent https://orcid.org/0000-0002-3288-2015
Sordet, Christelle https://orcid.org/0000-0001-6382-8735
Tropé, Sonia https://orcid.org/0000-0002-7321-9287
Gossec, Laure https://orcid.org/0000-0002-4528-310X
Beauvais, Catherine https://orcid.org/0000-0002-9872-4298
-
Funding
Funding for this research was provided by:
Centre hospitalier Universitaire de Clermont-Ferrand (AOI 2016)
- License Information
-
More Information
Article History
Received: 9 November 2021
Accepted: 1 January 2022
First Online: 7 April 2022
Declarations
:
: None of the authors has any conflicts of interest to declare related to this study.
: The study was approved by Clermont-Ferrand (France) Advisory Committee on Information Processing in Material Research in the Field of Health N° 15 863 and the French national data protection agency. Patients received oral and written information on the objectives of the study and signed informed consent before entering the study.
: Catherine Beauvais: research grants from BMS, Fresenius Kabi, Lilly, Mylan. Advisory board: Novartis and Sandoz. Occasional speaker fees from BMS, Abbvie, MSD, Mylan, Pfizer, Roche, Sanofi, and UCB. Christelle Sordet reports occasional consulting fees from Abbvie, UCB, Lilly, Nordic, GSK, Roche Chugaï, and BMS. Laure Gossec reports research grants from Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB.
: Deidentified participant data will be available upon request by contacting the principal investigator Malory Rodère <u>mrodere@chu-clermontferrand.fr</u> and/or the Data manager Bruno Pereira MD PhD <u>bpereira@chu-clermontferrand.fr.</u> Reuse of data is permitted with a signed data access agreement.
